SAMSUNG-ELECTRONICS
12.2.2020 11:05:04 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its next-generation 108-megapixel (Mp) image sensor, Samsung ISOCELL Bright HM1. With a spectrum of light-enhancing technologies spanning from Nonacell and Smart-ISO to real-time HDR, ISOCELL Bright HM1 allows brighter and more detailed 108Mp photographs and crystal-clear 8K videos at 24 frames per second (fps), even under extreme lighting conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005343/en/
“To capture meaningful moments in our lives, Samsung has been driving innovations in pixel and logic technologies that enable ISOCELL image sensors to take astounding photographs even when lighting conditions aren’t ideal,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “By adopting Nonacell and Smart-ISO technologies, the 108Mp ISOCELL Bright HM1 helps take vivid high-resolution pictures across a wide range of lighting environments.”
At a 1/1.33” scale with 108-million 0.8μm pixels, the ISOCELL Bright HM1 features the industry's first state-of-the-art Nonacell technology, which delivers brighter images in low-light settings. In 2017, Samsung introduced Tetracell, a pixel-binning technology with a special two-by-two array that merges four neighboring pixels to work as a single large pixel. Nonacell is an enhanced version of Tetracell with a three-by-three pixel structure. In the HM1, Nonacell merges nine neighboring 0.8μm pixels to mimic a large 2.4μm pixel, more than doubling Tetracell’s light absorption.
As the number of adjoined cells increase, so does color interference, making pixel-binning technologies more challenging, While such difficulties had limited Nonacell to a theory, the HM1 was able to realize the method by adopting Samsung’s ISOCELL Plus technology, which dramatically reduces crosstalk and minimizes optical loss as well as light reflection.
For ultimate results under any lighting condition, the HM1 supplements Nonacell with several other advanced pixel technologies. For example, the HM1’s Smart-ISO technology produces vivid and vibrant images by intelligently selecting the optimal ISO. High ISOs are used in darker settings while low ISOs are better for brighter environments to control light saturation.
In challenging mixed-light environments for photo-taking, the HM1’s real-time HDR technology optimizes exposures, producing more natural looking videos and still photographs. By assigning the most appropriate exposure lengths to each pixel, the HM1 is able to capture scenes in multiple exposures simultaneously, generating HDR images in real-time for both preview and capture modes. For sharper results, the HM1 supports a gyro-based electronic image stabilization (EIS) and Super-PD, an advanced phase detection technology for fast and accurate auto-focus.
The HM1 allows users to preview and capture full shots and close-ups of the subject at up to 3x lossless zoom, preserving the quality of the image. This is made possible by the sensor directly converting the pixels using an embedded hardware IP, rather than having the task delegated to the mobile processor. With 108-million pixels, the sensor is also able to produce images up to 3x zoom at a 12Mp resolution without upscaling.
Samsung ISOCELL Bright HM1 is currently in mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom